Mediar Therapeutics

Health Care · Biotechnology
Data updated Nov 20, 2026Money ledger: 1 record from 1 sourceAnnounced 1Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 20, 2026

New perspective. Novel targets. Clinical trials. The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in organ systems. By deactivating the myofibroblast, we hope to slow fibrosis and possibly reverse it.

Employees
51-200estimated range

These are the key facts about Mediar Therapeutics on Alion as of Nov 20, 2026. The latest round is Series B of $76M, announced in 2026.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Mediar Therapeutics has $76M paid in by investors, lenders and donors.

$76MPaid in
Money innewest first
Equity raised
Jan 2026 · Series B
$76MPaid
Money by yearUSD, rounds and grants
2026$76M1 record
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Sources name ICG, Amplitude Ventures among the owners or investors of Mediar Therapeutics.

Named investors, no share stated2
Holders and shares as each register or filing states them.

Products

Products →

Mediar Therapeutics has 6 clinical trials on record, 3 under way.

Clinical trials
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
phase 1 · under way · 88 participants · Healthy Adult Participants; Diabetic Kidney Disease
May 2026
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
phase 2 · under way · 85 participants · Diffuse Cutaneous Systemic Sclerosis
Apr 2026
Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males
phase 1 · completed · 8 participants · Healthy Adult Male
Feb 2026
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.
Sources: the outlets named on each headline, each story once

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices